<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82221">
  <stage>Registered</stage>
  <submitdate>16/08/2007</submitdate>
  <approvaldate>28/02/2008</approvaldate>
  <actrnumber>ACTRN12608000111370</actrnumber>
  <trial_identification>
    <studytitle>Prevalence of epiphora in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy</studytitle>
    <scientifictitle>A study to assess the incidence of tearing as a consequence of docetaxel chemotherapy in women with early breast cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Epiphora</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Epiphora</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>To measure the incidence of tearing by symptom review. clinical examination and Computerised tomography Dacrocystogram from baseline to 3 months following completion of chemotherapy</interventions>
    <comparator>Nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the frequency and severity of tearing in a group of consecutive patients receiving adjuvant docetaxel-based chemotherapy at 2 centres</outcome>
      <timepoint>Baseline, mid chemotherapy and 3 months after chemotherapy</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of epiphora</outcome>
      <timepoint>Baseline, after 3 cycles and at 12 weeks following chmoetherapy</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Proportion of patient who develop lacrimal duct stenosis</outcome>
      <timepoint>Before, during and after chemotherapy given</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To assess the efficacy of a conservative approach versus surgical intervention in a subset of patients with documented lacrimal stenosis</outcome>
      <timepoint>Baseline, mid chemotherapy and 3 months after chemotherapy</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of other eye pathology</outcome>
      <timepoint>Before, during and after chemotherapy given</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Women with early breast cancer receiving docetaxel-based chemotherapy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Tearing present prior to commencement of chemotherapy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/02/2008</anticipatedstartdate>
    <actualstartdate>30/11/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate>1/06/2010</actualenddate>
    <samplesize>100</samplesize>
    <actualsamplesize>85</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Mount Hospital - Perth</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Sanofi Aventis</primarysponsorname>
    <primarysponsoraddress>12-24 Talavera Road
Macquarie Park, NSW 2113
+61 (0)2 8666 2000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Sanofi Aventis</fundingname>
      <fundingaddress>sanofi-aventis
Talavera Corporate Centre
Building D
12-24 Talavera Road
Macquarie Park, NSW 2113
+61 (0)2 8666 2000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Richard De Boer</othercollaboratorname>
      <othercollaboratoraddress>Western Hospital
Footscray
Victoria</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will monitor whether you develop tearing and if so, how frequent and severe this complaint is. It will involve assessment of theeyes before start chemotherapy, during and at the end of treatment.</summary>
    <trialwebsite />
    <publication>no publication was ever made for this trial</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Mount Hospital</ethicname>
      <ethicaddress>150 Mounts Bay Rd
Perth 6000
WA</ethicaddress>
      <ethicapprovaldate>31/07/2007</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>1/05/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Dr Arlene Chan</name>
      <address>Hollywood Private Hospital
Entrance 3, Lower Ground Floor
101 Monash Avenue
Nedlands WA 6009</address>
      <phone>618-94814522</phone>
      <fax />
      <email>admin.arlenechan@me.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Astrid Bauwens</name>
      <address>Hollywood Private Hospital
Entrance 3, Lower Ground Floor
101 Monash avenue, Nedlands WA 6009</address>
      <phone>+61 8 6500 5555</phone>
      <fax />
      <email>astrid.bauwens@bcrc-wa.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Astrid Bauwens</name>
      <address>Hollywood Private Hospital
Entrance 3, Lower Ground Floor
101 Monash Avenue 
Nedlands WA 6009</address>
      <phone>+ 61 8 6500 5555</phone>
      <fax />
      <email>astrid.bauwens@bcrc-wa.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Arlene Chan</name>
      <address>Hollywood Private Hospital 
Entrance 3, Lower Ground Floor
101 Monash Avenue, Nedlands WA 6009</address>
      <phone>+ 08 6500 5555</phone>
      <fax />
      <email>admin.arlenechan@me.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>